The University of Southampton
University of Southampton Institutional Repository

Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis

Boonen, Steven, Marin, Fernando, Obermayer-Pietsch, Barbara, Simoes, Maria E., Barker, Clare, Glass, Emmett V., Hadji, Peyman, Lyritis, George, Oertel, Heide, Nickelsen, Thomas and McCloskey, Eugene V. for the EUROFORS Investigators (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis Journal of Clinical Endocrinology and Metabolism, 93, (3), pp. 852-860. (doi:10.1210/jc.2007-0711).

Record type: Article


INTRODUCTION: EUROFORS was a 2-yr prospective, randomized trial of postmenopausal women with established osteoporosis, designed to investigate various sequential treatments after teriparatide 20 microg/d for 1 yr. The present secondary analysis examined the effects of 2 yr of open-label teriparatide in women previously treated with antiresorptive drugs for at least 1 yr.
METHODS: A subgroup of 245 women with osteoporosis who had 2 yr of teriparatide treatment were stratified by previous predominant antiresorptive treatment into four groups: alendronate (n=107), risedronate (n=59), etidronate (n=30), and non-bisphosphonate (n=49). Bone mineral density (BMD) at the lumbar spine and hip was determined after 6, 12, 18, and 24 months, and bone formation markers were measured after 1 and 6 months.
RESULTS: Significant increases in bone formation markers occurred in all groups after 1 month of teriparatide treatment. Lumbar spine BMD increased at all visits, whereas a transient decrease in hip BMD, which was subsequently reversed, was observed in all groups. BMD responses were similar in all previous antiresorptive groups. Previous etidronate users showed a higher increase at the spine but not at the hip BMD. Duration of previous antiresorptive therapy and lag time between stopping previous therapy and starting teriparatide did not affect the BMD response at any skeletal site. Treatment-emergent adverse events were similar to those reported in treatment-naive postmenopausal women with osteoporosis treated with teriparatide.
CONCLUSIONS: Teriparatide induces positive effects on BMD and markers of bone formation in postmenopausal women with established osteoporosis, regardless of previous long-term exposure to antiresorptive therapies.

Full text not available from this repository.

More information

Published date: March 2008
Keywords: peptide fragments, women, exposure, drug therapy, responses, spine, humans, adverse effects, blood, teriparatide, bone, postmenopausal, osteoporosis, aged, therapeutic use, methods, hip, female, middle aged, physiopathology, osteogenesis, therapy, analysis, procollagen, prevention & control, time, prospective studies, bone density, bone resorption, bone density conservation agents, research, drug effects


Local EPrints ID: 60926
ISSN: 0021-972X
PURE UUID: 751522ef-df00-418a-aa3f-643b9a980fb9

Catalogue record

Date deposited: 19 Sep 2008
Last modified: 17 Jul 2017 14:23

Export record



Author: Steven Boonen
Author: Fernando Marin
Author: Barbara Obermayer-Pietsch
Author: Maria E. Simoes
Author: Clare Barker
Author: Emmett V. Glass
Author: Peyman Hadji
Author: George Lyritis
Author: Heide Oertel
Author: Thomas Nickelsen
Author: Eugene V. for the EUROFORS Investigators McCloskey

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.